A novel association between high red blood cell alloimmunization rates and hereditary hemorrhagic telangiectasia

A novel association between high red blood cell alloimmunization rates and hereditary hemorrhagic... ABBREVIATIONSACVRL1/ALK1activin receptor‐like kinaseAPC(s)antigen‐presenting cell(s)AVM(s)arteriovenous malformation(s)DC(s)dendritic cell(s)ENGendoglinHHThereditary hemorrhagic telangiectasiaAlloimmunization to non‐ABO red blood cell (RBC) antigens is one of the most common complications of repeated RBC transfusions. Alloimmunization rates are approximately 1% to 3% in general hospital–based patients and can reach up to 50% in transfusion‐dependent patients such as patients with sickle cell disease. Non‐ABO RBC alloantibodies increase the risk of immediate and delayed hemolytic transfusion reactions, which are one of the leading causes of transfusion‐related mortality reported to the Food and Drug Administration. Patients with alloantibodies are also more likely to experience delays in transfusions because the numbers of compatible RBCs for transfusions are limited; such delays can also lead to complications resulting in morbidity and mortality. In addition, maternal alloantibodies in the setting of pregnancy may lead to severe hemolytic disease of the fetus and newborn. Because of its frequency and associated clinical complications, numerous studies of alloimmunization have been undertaken to discover underlying causes that drive alloantibody development. To date, alloimmunization has been associated with multiple risk factors including transfusion load, age, sex, inflammatory status, immunogenicity of RBC antigens, RBC unit processing, and modifications—all of these potentially affect alloimmunization. However, the association between alloimmunization and specific disease http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Transfusion Wiley

A novel association between high red blood cell alloimmunization rates and hereditary hemorrhagic telangiectasia

Loading next page...
 
/lp/wiley/a-novel-association-between-high-red-blood-cell-alloimmunization-rates-kSh2TaeGxr
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
© 2018 AABB
ISSN
0041-1132
eISSN
1537-2995
D.O.I.
10.1111/trf.14451
Publisher site
See Article on Publisher Site

Abstract

ABBREVIATIONSACVRL1/ALK1activin receptor‐like kinaseAPC(s)antigen‐presenting cell(s)AVM(s)arteriovenous malformation(s)DC(s)dendritic cell(s)ENGendoglinHHThereditary hemorrhagic telangiectasiaAlloimmunization to non‐ABO red blood cell (RBC) antigens is one of the most common complications of repeated RBC transfusions. Alloimmunization rates are approximately 1% to 3% in general hospital–based patients and can reach up to 50% in transfusion‐dependent patients such as patients with sickle cell disease. Non‐ABO RBC alloantibodies increase the risk of immediate and delayed hemolytic transfusion reactions, which are one of the leading causes of transfusion‐related mortality reported to the Food and Drug Administration. Patients with alloantibodies are also more likely to experience delays in transfusions because the numbers of compatible RBCs for transfusions are limited; such delays can also lead to complications resulting in morbidity and mortality. In addition, maternal alloantibodies in the setting of pregnancy may lead to severe hemolytic disease of the fetus and newborn. Because of its frequency and associated clinical complications, numerous studies of alloimmunization have been undertaken to discover underlying causes that drive alloantibody development. To date, alloimmunization has been associated with multiple risk factors including transfusion load, age, sex, inflammatory status, immunogenicity of RBC antigens, RBC unit processing, and modifications—all of these potentially affect alloimmunization. However, the association between alloimmunization and specific disease

Journal

TransfusionWiley

Published: Jan 1, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off